Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

Trial Identifier: D8224C00001
Sponsor: AstraZeneca
NCTID:: NCT04872621
Start Date: June 2021
Primary Completion Date: September 2024
Study Completion Date: September 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan, D8224C00001
Japan Aomori, Japan, D8224C00001
Japan Fukuoka, Japan, D8224C00001
Japan Gunma, Japan, D8224C00001
Japan Gunma, Japan
Japan Hokkaido, Japan, D8224C00001
Japan Hyogo, Japan
Japan Hyogo, Japan, D8224C00001
Japan Ibaraki, Japan
Japan Ibaraki, Japan, D8224C00001
Japan Iwate, Japan
Japan Kagoshima, Japan, D8224C00001
Japan Kumamoto, Japan
Japan Kyoto, Japan
Japan Mie, Japan
Japan Miyagi, Japan, D8224C00001
Japan Miyagi, Japan
Japan Nagasaki, Japan, D8224C00001
Japan Okayama, Japan
Japan Saitama, Japan, D8224C00001
Japan Shiga, Japan, D8224C00001
Japan Shizuoka, Japan, D8224C00001
Japan Tottori, Japan
Japan Wakayama, Japan, D8224C00001
Japan Wakayama, Japan
Japan Yamaguchi, Japan